Roche Holding AG
RO
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
stocks
6 undervalued stocks with low beta
Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
stocks
An undervalued, wide-moat name in healthcare
Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,241.10 | 0.50 | -0.01% |
| CAC 40 | 7,757.93 | 14.00 | 0.18% |
| DAX 40 | 24,020.61 | 25.60 | -0.11% |
| Dow JONES (US) | 45,565.23 | 147.16 | 0.32% |
| FTSE 100 | 9,210.66 | 44.84 | -0.48% |
| HKSE | 24,998.82 | 202.94 | -0.81% |
| NASDAQ | 21,590.14 | 45.87 | 0.21% |
| Nikkei 225 | 42,828.79 | 308.52 | 0.73% |
| NZX 50 Index | 12,903.08 | 41.24 | 0.32% |
| S&P 500 | 6,481.40 | 15.46 | 0.24% |
| S&P/ASX 200 | 8,980.00 | 9.50 | 0.11% |
| SSE Composite Index | 3,843.60 | 43.25 | 1.14% |